BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 17634838)

  • 1. Waldenström macroglobulinemia.
    Ghobrial IM; Witzig TE
    Curr Treat Options Oncol; 2004 Jun; 5(3):239-47. PubMed ID: 15115652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Waldenstrom macroglobulinemia.
    Leleu X; Roccaro AM; Moreau AS; Dupire S; Robu D; Gay J; Hatjiharissi E; Burwik N; Ghobrial IM
    Cancer Lett; 2008 Oct; 270(1):95-107. PubMed ID: 18555588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update on therapeutic options in Waldenström macroglobulinemia.
    Leleu X; Gay J; Roccaro AM; Moreau AS; Poulain S; Dulery R; Champs BB; Robu D; Ghobrial IM
    Eur J Haematol; 2009 Jan; 82(1):1-12. PubMed ID: 19087134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bortezomib-Dexamethasone, Rituximab, and Cyclophosphamide as First-Line Treatment for Waldenström's Macroglobulinemia: A Prospectively Randomized Trial of the European Consortium for Waldenström's Macroglobulinemia.
    Buske C; Dimopoulos MA; Grunenberg A; Kastritis E; Tomowiak C; Mahé B; Troussard X; Hajek R; Viardot A; Tournilhac O; Aurran T; Lepretre S; Zerazhi H; Hivert B; Leblond V; de Guibert S; Brandefors L; Garcia-Sanz R; Gomes da Silva M; Kimby E; Schmelzle B; Kaszynski D; Dreyhaupt J; Muche R; Morel P
    J Clin Oncol; 2023 May; 41(14):2607-2616. PubMed ID: 36763945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Waldenström macroglobulinemia: 2023 update on diagnosis, risk stratification, and management.
    Gertz MA
    Am J Hematol; 2023 Feb; 98(2):348-358. PubMed ID: 36588395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Waldenström's macroglobulinemia: a clinical perspective in the era of novel therapeutics.
    Dimopoulos MA; Kastritis E; Ghobrial IM
    Ann Oncol; 2016 Feb; 27(2):233-40. PubMed ID: 26598544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New Therapeutic Approaches for Waldenstrom Macroglobulinemia.
    Stedman J; Roccaro A; Leleu X; Ghobrial IM
    Drugs Future; 2010 Jan; 35(1):53-58. PubMed ID: 21869855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does Bortezomib-Dexamethasone-Rituximab-Cyclophosphamide Play a Role in the Treatment of Waldenström's Macroglobulinemia?
    Sarosiek S; Treon SP; Branagan AR; Castillo JJ
    J Clin Oncol; 2023 Aug; 41(24):4059-4060. PubMed ID: 37348023
    [No Abstract]   [Full Text] [Related]  

  • 9. Novel agents in Waldenstrom Macroglobulinemia.
    Sacco A; Leleu X; Rossi G; Ghobrial IM; Roccaro AM
    Open J Hematol; 2010 May; 1():. PubMed ID: 22844582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A SCID-hu in vivo model of human Waldenström macroglobulinemia.
    Tassone P; Neri P; Kutok JL; Tournilhac O; Santos DD; Hatjiharissi E; Munshi V; Venuta S; Anderson KC; Treon SP; Munshi NC
    Blood; 2005 Aug; 106(4):1341-5. PubMed ID: 15886318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relapsed Waldenstrom's Macroglobulinemia and Therapy-Related Myelodysplastic Syndrome with Complex Cytogenetics: A Treatment Dilemma.
    Kalantri S; Singh I; Yang L; Abuelgasim KA
    Case Rep Oncol; 2023; 16(1):351-356. PubMed ID: 37384207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapy-Related Myeloid Neoplasms in Chronic Lymphocytic Leukemia and Waldenstrom's Macroglobulinemia.
    Ricci F; Tedeschi A; Montillo M; Morra E
    Mediterr J Hematol Infect Dis; 2011; 3(1):e2011031. PubMed ID: 21869917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Acquired von Willebrand syndrome in three patients and literature review].
    Ouyang HY; Yu ZJ; Yin J; Zhao XJ; Wang ZY; Zhang W; Ma ZN; Su J; Bai X; Ruan CG
    Zhonghua Xue Ye Xue Za Zhi; 2016 Aug; 37(8):692-5. PubMed ID: 27587252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic effects of thalidomide in hematologic disorders: a review.
    Xu M; Hou Y; Sheng L; Peng J
    Front Med; 2013 Sep; 7(3):290-300. PubMed ID: 23856973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of Waldenstrom's Macroglobulinemia.
    Dimopoulos MA; Anagnostopoulos A
    Curr Treat Options Oncol; 2007 Apr; 8(2):144-53. PubMed ID: 17634838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia.
    Dimopoulos MA; Gertz MA; Kastritis E; Garcia-Sanz R; Kimby EK; Leblond V; Fermand JP; Merlini G; Morel P; Morra E; Ocio EM; Owen R; Ghobrial IM; Seymour J; Kyle RA; Treon SP
    J Clin Oncol; 2009 Jan; 27(1):120-6. PubMed ID: 19047284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment recommendations in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
    Gertz MA; Anagnostopoulos A; Anderson K; Branagan AR; Coleman M; Frankel SR; Giralt S; Levine T; Munshi N; Pestronk A; Rajkumar V; Treon SP
    Semin Oncol; 2003 Apr; 30(2):121-6. PubMed ID: 12720120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Waldenström's macroglobulinemia: a review of therapy.
    Gertz MA
    Leuk Lymphoma; 2002 Aug; 43(8):1517-26. PubMed ID: 12400593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bortezomib as a treatment option in patients with Waldenström macroglobulinemia.
    Dimopoulos MA; Chen C; Kastritis E; Gavriatopoulou M; Treon SP
    Clin Lymphoma Myeloma Leuk; 2010 Apr; 10(2):110-7. PubMed ID: 20371443
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.